A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors
Publication
, Conference
Burris, H; LoRusso, P; Jones, S; McCormick, J; Wilcutt, N; Hodge, J; Bush, P; Pandite, L; Sabry, J; Ho, P
Published in: European Journal of Cancer
2003
Duke Scholars
Published In
European Journal of Cancer
ISSN
0959-8049
Publication Date
2003
Volume
1
Issue
5
Start / End Page
S172 / S172
Publisher
Elsevier
Related Subject Headings
- Oncology & Carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Burris, H., LoRusso, P., Jones, S., McCormick, J., Wilcutt, N., Hodge, J., … Ho, P. (2003). A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. In European Journal of Cancer (Vol. 1, pp. S172–S172). Elsevier.
Burris, H., P. LoRusso, S. Jones, J. McCormick, N. Wilcutt, J. Hodge, P. Bush, L. Pandite, J. Sabry, and P. Ho. “A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors.” In European Journal of Cancer, 1:S172–S172. Elsevier, 2003.
Burris H, LoRusso P, Jones S, McCormick J, Wilcutt N, Hodge J, et al. A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. In: European Journal of Cancer. Elsevier; 2003. p. S172–S172.
Burris, H., et al. “A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors.” European Journal of Cancer, vol. 1, no. 5, Elsevier, 2003, pp. S172–S172.
Burris H, LoRusso P, Jones S, McCormick J, Wilcutt N, Hodge J, Bush P, Pandite L, Sabry J, Ho P. A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. European Journal of Cancer. Elsevier; 2003. p. S172–S172.
Published In
European Journal of Cancer
ISSN
0959-8049
Publication Date
2003
Volume
1
Issue
5
Start / End Page
S172 / S172
Publisher
Elsevier
Related Subject Headings
- Oncology & Carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis